CJC-1295 (No DAC) + Ipamorelin Product Brief

1. Stack Overview

CJC-1295 (No DAC) combined with Ipamorelin is a commonly researched peptide stack designed to study growth hormone signaling pathways.

CJC-1295 (No DAC), also known as Modified GRF 1-29, is a synthetic analog of growth hormone releasing hormone (GHRH), while Ipamorelin is a selective ghrelin receptor agonist. Together, the peptides are studied for their complementary effects on stimulating endogenous growth hormone release while maintaining a pulsatile hormone pattern.

2. Mechanism of Interest

This peptide combination is studied for several complementary biological mechanisms:

• CJC-1295 (No DAC) stimulates the GHRH receptor to promote growth hormone release
  • Ipamorelin activates the ghrelin receptor (GHS-R1a)
  • The combination may support natural pulsatile GH secretion
  • Potential increase in IGF-1 signaling pathways
  • May influence metabolic, recovery, and regenerative research pathways

3. Research Areas Being Explored

• Growth hormone pulsation research
  • Body composition studies
  • Recovery and regeneration pathways
  • Sleep and endocrine signaling research
  • Metabolic regulation studies

4. Safety and Regulatory Notes

CJC-1295 (No DAC) and Ipamorelin are not approved by the FDA for medical treatment and are commonly distributed as research compounds.

This document is intended for informational and research product description purposes only.